Related Experiment Video
Updated: Apr 2, 2026
10:03
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
Published on: February 28, 2013
26.7K
Behavioral Programs for Type 1 Diabetes Mellitus: A Systematic Review and Meta-analysis
Annals of Internal Medicine
|September 29, 2015
Summary
Behavioral programs for type 1 diabetes show short-term benefits in glycemic control, specifically reducing HbA1c levels. However, long-term effects and improvements in other health outcomes remain unproven.
Area of Science:
- Endocrinology
- Behavioral Medicine
- Public Health
Background:
- The effectiveness of behavioral self-management programs for type 1 diabetes mellitus requires further clarification.
- Existing evidence on the impact of behavioral interventions on type 1 diabetes management is limited.
Purpose of the Study:
- To evaluate the effects of behavioral programs on clinical, behavioral, and health outcomes in type 1 diabetes patients.
- To identify potential moderating factors influencing the effectiveness of these behavioral interventions.
Main Methods:
- A systematic review of 36 prospective, controlled studies published between 1993 and 2015.
- Studies included participants of all age groups, comparing behavioral programs with usual care or active controls.
- Data extraction and quality assessment were performed by multiple reviewers.
Main Results:
- Moderate evidence indicates a short-term reduction in glycated hemoglobin (HbA1c) at 6 months post-intervention.
- No significant long-term differences in HbA1c or generic quality of life were observed compared to controls.
- Adults showed a greater benefit in glycemic control than youth; individual delivery of programs appeared beneficial.
Conclusions:
- Behavioral programs offer short-term glycemic control benefits for type 1 diabetes but lack evidence for other outcomes.
- All included studies had a medium to high risk of bias, indicating a need for higher-quality research.
- Scarce evidence exists for many outcomes, highlighting limitations in the current research landscape.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
01:22Diabetes Mellitus: Overview and Type I Subtype
6.0K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
6.0K
01:22Diabetes Mellitus: Type 2 and Gestational
5.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.5K
01:16Insulin: Dosing Regimen and Adverse Effects
1.2K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.2K
01:36Carbohydrate Metabolism
15.0K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
15.0K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
959
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
959